- Home
- CRDF vs ALDX Comparison
CRDF vs ALDX Comparison
Compare CRDF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ALDX
- Stock Information
- Founded
- CRDF 1999
- ALDX 2004
- Country
- CRDF United States
- ALDX United States
- Employees
- CRDF N/A
- ALDX N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- ALDX Health Care
- Exchange
- CRDF Nasdaq
- ALDX Nasdaq
- Market Cap
- CRDF 288.7M
- ALDX 398.3M
- IPO Year
- CRDF N/A
- ALDX 2014
- Fundamental
- Price
- CRDF $3.06
- ALDX $5.48
- Analyst Decision
- CRDF Strong Buy
- ALDX Strong Buy
- Analyst Count
- CRDF 4
- ALDX 2
- Target Price
- CRDF $12.00
- ALDX $10.00
- AVG Volume (30 Days)
- CRDF 1.1M
- ALDX 901.3K
- Earning Date
- CRDF 05-01-2025
- ALDX 05-01-2025
- Dividend Yield
- CRDF N/A
- ALDX N/A
- EPS Growth
- CRDF N/A
- ALDX N/A
- EPS
- CRDF N/A
- ALDX N/A
- Revenue
- CRDF $683,000.00
- ALDX N/A
- Revenue This Year
- CRDF N/A
- ALDX N/A
- Revenue Next Year
- CRDF N/A
- ALDX N/A
- P/E Ratio
- CRDF N/A
- ALDX N/A
- Revenue Growth
- CRDF 39.96
- ALDX N/A
- 52 Week Low
- CRDF $2.01
- ALDX $3.10
- 52 Week High
- CRDF $6.38
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CRDF 32.85
- ALDX 37.89
- Support Level
- CRDF $3.65
- ALDX $6.30
- Resistance Level
- CRDF $3.88
- ALDX $6.73
- Average True Range (ATR)
- CRDF 0.21
- ALDX 0.52
- MACD
- CRDF -0.08
- ALDX -0.14
- Stochastic Oscillator
- CRDF 9.30
- ALDX 20.71
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.